ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Frequently asked questions
What sector does ADMA Biologics, Inc (ADMA) operate in?
ADMA Biologics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is ADMA Biologics, Inc (ADMA) current stock price?
As of the latest data, ADMA Biologics, Inc stock price is $9.41, with a previous close of $9.63. ADMA Biologics, Inc lost -$0.22 in the last trading session, representing a -2.28% loss.
What is ADMA Biologics, Inc (ADMA) current market capitalization?
ADMA Biologics, Inc market cap is approximately 2.11 billion.
What is ADMA Biologics, Inc (ADMA) Earnings Per Share (EPS)?
The trailing EPS is $0.70, and the forward EPS is $0.98.
What is ADMA Biologics, Inc (ADMA) Price-to-Earnings (P/E) ratio?
ADMA Biologics, Inc current P/E ratio is 13.44, with a forward P/E of 9.58.
What is ADMA Biologics, Inc (ADMA) EBITDA?
ADMA Biologics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 57.28 million.
Does ADMA Biologics, Inc (ADMA) pay dividends?
No. ADMA Biologics, Inc does not pay a dividend.
How did ADMA Biologics, Inc (ADMA) perform in its most recent earnings report?
In the last report (June 30, 2026), ADMA Biologics, Inc posted an EPS surprise of 0% and a revenue surprise of -0.77%.
What is ADMA Biologics, Inc (ADMA) beta (volatility) score?
ADMA Biologics, Inc has a beta of 0.768, indicating lower volatility than the overall market.
